• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • Store
  • ION Awards
  • Podcasts
  • Full Measure
    • Full Measure Cover Stories
  • Donate
  • Bestseller "Slanted"

Sharyl Attkisson

Untouchable Subjects. Fearless, Nonpartisan Reporting.

  • US
  • World
  • Business
  • Health
    • Vaccine, Medical links
    • Omicron Lab Origin
    • Covid-19 Origins
    • Covid-19 Natural Immunity
    • Covid-19 Vaccine Concerns Summary
    • Covid-19 Vaccine: 80 Common Adverse Events
  • The Censored
  • Special Investigations
    • Attkisson v. DOJ
    • Media Mistakes, Biden Era
    • Media Mistakes on Trump
    • Other investigations
      • Benghazi
      • "Collusion v. Trump" TL
      • Election 2020
      • Fake News
      • Fast & Furious
      • Obamacare
      • Obama Surveillance TL
      • Other investigations
      • Ukraine 'Sabotage' of Trump TL

(READ) New drug for hemophilia is most expensive in the world at $3.5 million per treatment

Dated: November 30, 2022 by Sharyl Attkisson Leave a Comment

      

A new drug to treat hemophilia has been approved by the FDA. The drug is called Hemgenix, and its price tag makes it the most expensive drug in the world.

According to reports, CSL Behring, which makes the gene therapy treatment, is setting the price at an incredible $3.5 million per treatment.

Hemgenix is approved to treat adults who have hemophilia B. That's an illness in which patients cannot product a crucial blot-clotting protein called Factor IX. The treatment involves a one-time intravenous infusion.

As to who will be able to afford $3.5 million per treatment? Experts say the cost is borne by all insured patients, because insurance will generally cover the cost of any patients approved for treatment.

An article in "Gene Online" states, "All gene therapies are expensive due to the research, development, and costs to produce the products, and price tags of greater than $2 million are becoming more common."

Read the FDA statement on the approval here and below.


FDA Approves First Gene Therapy to Treat Adults with Hemophilia B

Today, the U.S. Food and Drug Administration approved Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

โ€œGene therapy for hemophilia has been on the horizon for more than two decades. Despite advancements in the treatment of hemophilia, the prevention and treatment of bleeding episodes can adversely impact individualsโ€™ quality of life,โ€ said Peter Marks, M.D., Ph.D., director of the FDAโ€™s Center for Biologics Evaluation and Research. โ€œTodayโ€™s approval provides a new treatment option for patients with Hemophilia B and represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this form of hemophilia.โ€

Hemophilia B is a genetic bleeding disorder resulting from missing or insufficient levels of blood clotting Factor IX, a protein needed to produce blood clots to stop bleeding. Symptoms can include prolonged or heavy bleeding after an injury, surgery, or dental procedure; in severe cases, bleeding episodes can occur spontaneously without a clear cause. Prolonged bleeding episodes can lead to serious complications, such as bleeding into joints, muscles or internal organs, including the brain. 

Most individuals who have Hemophilia B and experience symptoms are men. The prevalence of Hemophilia B in the population is about one in 40,000; Hemophilia B represents about 15% of patients with hemophilia. Many women carriers of the disease have no symptoms. However, an estimated 10-25% of women carriers have mild symptoms; in rare cases, women may have moderate or severe symptoms. 

Treatment typically involves replacing the missing or deficient clotting factor to improve the bodyโ€™s ability to stop bleeding and promote healing. Patients with severe Hemophilia B typically require a routine treatment regimen of intravenous (IV) infusions of Factor IX replacement products to maintain sufficient levels of clotting factor to prevent bleeding episodes.

Hemgenix is a one-time gene therapy product given as a single dose by IV infusion. Hemgenix consists of a viral vector carrying a gene for clotting Factor IX. The gene is expressed in the liver to produce Factor IX protein, to increase blood levels of Factor IX and thereby limit bleeding episodes. 

The safety and effectiveness of Hemgenix were evaluated in two studies of 57 adult men 18 to 75 years of age with severe or moderately severe Hemophilia B. Effectiveness was established based on decreases in the menโ€™s annualized bleeding rate (ABR). In one study, which had 54 participants, the subjects had increases in Factor IX activity levels, a decreased need for routine Factor IX replacement prophylaxis, and a 54% reduction in ABR compared to baseline.

The most common adverse reactions associated with Hemgenix included liver enzyme elevations, headache, mild infusion-related reactions and flu-like symptoms. Patients should be monitored for adverse infusion reactions and liver enzyme elevations (transaminitis) in their blood.ย 

The Lemonade Mermaid Store

Unique gifts for Land or Sea Mermaids, Mer-pets and Little Mermaids!

Left: Our signature Blue Fins Earrings

SHOP NOW


      
[the_ad id="17661"]

About Sharyl Attkisson

Emmy-Award Winning Investigative Journalist, New York Times Best Selling Author, Host of Sinclair's Full Measure

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Coming Soon

The Bad Shirts: High-Quality, Wearable Humor

The Sharyl Attkisson Store

Buy Great, Original Products & Support Independent Journalism

Subscribe

Get the Latest Stories Straight to Your Inbox

SUBSCRIBE TO SHARYL’S RUMBLE CHANNEL


Follow Sharyl Attkisson

  • Facebook
  • Instagram
  • RSS
  • Twitter
  • YouTube



Footer

Pages

  • Home
  • About
  • Podcast
  • Support
  • Contact

Sitemap

2ndary Pages

  • Full Measure Stations
  • Privacy Policy
  • Terms of Use
  • Newsletter
  • Returns & Refunds Policy

SPECIAL INVESTIGATIONS

  • Attkisson v. DOJ/FBI
  • Benghazi
  • Election 2020
  • Fake News
  • Fast & Furious
  • Obamacare

Copyright © 2023 ยท Log in